Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

Preliminary data from an ongoing Phase 2 trial evaluating satraplatin plus Taxol(R) (paclitaxel) in the first-line treatment of patients with advanced non-small cell lung cancer were also published in the ASCO educational book (Shipley, D. et al. Phase II trial of satraplatin and paclitaxel in the first-line treatment of advanced non-small cell lung cancer). Data from 24 patients were available for analysis; a total of approximately 40 patients are expected to be enrolled in the study. This preliminary analysis showed that satraplatin plus Taxol appears to have activity in this treatment setting. In an effort to reduce myelosuppression in the study, the satraplatin dose has been lowered to 70 mg/m2 from 80 mg/m2. The study continues to enroll and follow patients.

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration. Satraplatin is an oral compound that clinical trial patients are able to take at home. Satraplatin is not currently approved by the FDA in the United States, by the EMEA in the European Union or any other regulatory authority and no conclusions can or should be drawn regarding its safety and efficacy.

A Phase 3 registrational trial, called SPARC, is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone- refractory prostate cancer whose prior chemotherapy has failed. Data from the trial on progression-free survival and on safety have been presented at recent medical conferences.

GPC Biotech has a co-development and license agreement with Pharmion GmbH, a wholly owned subsidiary of Pharmion Corporation, under which Pharmion has been granted exclusive commercialization rights to satraplatin for Europe and certain other territories.
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:6/30/2015)... ALISO VIEJO, Calif. , June 30, 2015 ... from the PRISM II study showing that treatment ... statistically significant reduction in symptoms of pseudobulbar affect ... or stroke. PBA is a distressing condition characterized ... crying resulting from certain neurologic diseases or brain ...
(Date:6/30/2015)... – Small Cap IR issues report. Recently, Arrayit Corporation ... blood card technology to Vivos, Global Genome Vault, the ... an impervious, impenetrable and permanent DNA storage vault, able ... Earth, a safe and secure nuclear blast-proof, underground shelter ... rapid collection, separation, drying and storage of human genomic ...
(Date:6/30/2015)... 2015  Egalet Corporation (Nasdaq: EGLT ... company focused on developing, manufacturing and marketing ... from a Category 3 human abuse liability ... oral oxycodone product candidate in late-stage clinical ... enough to require daily, around-the-clock opioid treatment ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7Small Cap IR - Empowering the Age of Genetic Enlightenment 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Technologies, Inc. (NYSE Amex: PTN ), ... for the treatment of diseases with significant unmet ... Dr. Carl Spana, President and Chief Executive Officer ... Eighth Annual Equity Conference.  The presentation is scheduled ...
... YORK, Jan. 16, 2012 Reportlinker.com announces ... available in its catalogue: , ... http://www.reportlinker.com/p0760637/Pharmaceutical-MA-in-the-Asia-Pacific-Region.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical ... continues in major developed markets, prompted by ...
Cached Medicine Technology:Palatin Technologies to Present at BOCEMb, Noble Financial Capital Markets' Eighth Annual Equity Conference 2Pharmaceutical M&A in the Asia Pacific Region 2Pharmaceutical M&A in the Asia Pacific Region 3Pharmaceutical M&A in the Asia Pacific Region 4
(Date:6/30/2015)... ... June 30, 2015 , ... ... it has more than doubled the size of its medical staff to further ... staff -- which includes physicians, nurse practitioners and physician assistants -- now totals ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... ) currently pending in a federal multidistrict litigation now underway in the U.S. ... its next monthly Status Conference. According to the Court’s calendar, that conference has ...
(Date:6/30/2015)... ... June 30, 2015 , ... Dr. Sammy Masri of ... medicine physician. He specializes in the diagnosis and treatment of non-surgical sports and other ... people who participate in recreational athletics and use exercise to stay healthy and active. ...
(Date:6/30/2015)... ... 2015 , ... MJH Associates today welcomed Jim ... & Analytics , a consultative healthcare market research practice that is part of ... offers quantitative and qualitative, custom and multi-client primary market research services to support ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... oncology centers are partnering to improve access to cancer prevention, screening and care ... Center (LCC) have announced an affiliation that will see Roswell Park faculty providing ...
Breaking Medicine News(10 mins):Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 4Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 5
... Seek Vote to Join More Than 55,000 Others Who Have ... Calif., Jan. 8 /PRNewswire-USNewswire/ -- Healthcare ... elections to join more than 55,000 other union members who ... International Union - United Healthcare Workers West (SEIU-UHW), rather than ...
... Quercetin , FRIDAY, Jan. 8 (HealthDay News) -- Researchers ... in hepatitis C infection, and they say the finding may ... which can lead to cirrhosis and liver cancer. , The ... can cause major side effects and aren,t effective in all ...
... of uridine, choline and DHA boosted memory of Alzheimer,s patients ... A combination of three nutrients might help improve memory in ... (synapses), a new study shows. , Uridine, choline and the ... precursors to the fatty molecules that make up brain cell ...
... , , - Subtle ... , PHILADELPHIA, Jan 8 Children with autism spectrum disorders (ASDs) ... children without ASDs, and measuring magnetic signals that mark this delay ... http://www.newscom.com/cgi-bin/prnh/20100108/DC34671 ) , Researchers at The Children,s Hospital ...
... Jan. 8 Gilbert Hospital expects patient volume at its ... and continued easing of the nationwide economic unrest have officials ... this community-based hospital. , "We are expecting smaller growth and ... east valley, but the state and the nation," said Randy ...
... , GILBERT, Ariz., Jan. 8 Gilbert Hospital continued ... patient visits through the emergency department, patient levels remained constant ... Doc in 31 Minutes" continued its success with more than ... certified physician within 31 minutes of arrival. Additionally, the average ...
Cached Medicine News:Health News:SEIU-UHW Members at 26 Hospitals and Nursing Homes Seeking Elections Against Group Started by the Union's Ousted Leaders 2Health News:SEIU-UHW Members at 26 Hospitals and Nursing Homes Seeking Elections Against Group Started by the Union's Ousted Leaders 3Health News:Key to Hepatitis C May Be Two Cellular Proteins 2Health News:Brain Imaging May Help Diagnose Autism 2Health News:Brain Imaging May Help Diagnose Autism 3Health News:Brain Imaging May Help Diagnose Autism 4Health News:Gilbert Hospital Forecasts Steady 2010 2Health News:Gilbert Hospital 2009 Emergency Department Year in Review 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: